ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.40 (+3.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ENANTA PHARMACEUTICALS INC reported revenue of $65.26M for the twelve months to Jun 30, 2026. Free cash flow was -$36.94M.
Revenue
$65.26M
TTM Q3 2026
Operating income
-$58.73M
TTM Q3 2026
Free cash flow
-$36.94M
TTM Q3 2026
EPS, diluted
-$3.84
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $331.92M
- P/E ratio
- –
- Price to sales
- 5.09
- Price to book
- 3.28
- Dividend yield
- –
- Free cash flow yield
- -11.13%
Fundamentals
- Revenue
- $65.26M
- Net income
- -$63.23M
- EPS, diluted
- -$3.84
- Free cash flow
- -$36.94M
- Book value per share
- $3.47
- Diluted shares
- 29M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$65.26M
Operating income
-$58.73M
Net income
-$63.23M
EPS, diluted
–
Free cash flow
-$36.94M
Reported periodTrailing twelve months